CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04052438
NCT04052438N/ACompleted

Predictive Inmunological Study to Assess the Rate of Gestation, Abortion and Live Newborn in Patients With Recurrent Abortions and Recurrent Implantation Failure.

IVI Madrid·observational·Posted Aug 9, 2019·Updated Aug 21, 2019

In Brief

An observational study evaluating HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn. for Maternal-Fetal KIR-HLA-C Compatibility. Completed, enrolled 200 participants.

Detailed Summary

The involvement of the immune system in the process of implantation and its modulation as a therapeutic line in these alterations, failure of implantation and repetition abortion are controversial and make it necessary to conduct clinical studies properly led and with a study population chosen by strict criteria in order to better understand the involvement of the different innate and adaptive immune mechanisms in the field of reproductive medicine and especially in clinically expressed failures recurrent implantation failure and recurrent abortions.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 9, 2019
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.9 years ago

Interventions

HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.other